Exelixis Inc (NAS:EXEL)
$ 20.91 -0.32 (-1.51%) Market Cap: 6.09 Bil Enterprise Value: 5.33 Bil PE Ratio: 32.52 PB Ratio: 2.90 GF Score: 91/100

Exelixis Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript

Jun 10, 2020 / 06:10PM GMT
Release Date Price: $23.13 (+2.23%)
Kyuwon Choi
Goldman Sachs Group, Inc., Research Division - Equity Analyst

Okay. Good afternoon, everyone. We'll continue with the next session. I'm Paul Choi, the SMid cap biotechnology analyst here at Goldman Sachs. And for our next session, I'm very pleased to host Exelixis. Joining us is the CEO, Mike Morrissey; and also on the line is Susan from Investor Relations.

And so as with prior sessions, with Exelixis here, what we'll do is let Mike kick it off with some introductory remarks, and then we'll go into the Q&A portion of the session. (Operator Instructions)

And so with that, Mike, I'll turn it over to you for some opening remarks, and then we'll go into the Q&A.

Michael M. Morrissey
Exelixis, Inc. - CEO, President & Director

All right. Fantastic, Paul. Thanks again for the invite. Sorry, we couldn't do this live, as usual, down in L.A., but it's great to be on the call with you and your team today.

Before I begin, I'll remind you that I'll be making forward-looking statements today. So please see our SEC

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot